Syncom Formulations (India) Limited

SYNCOMF

INE312C01025

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:21:14 2024-04-25 am EDT			5-day change	1st Jan Change
13.78 ^INR	-1.85%		+8.59%	-8.38%

Mar. 29	Syncom Formulations Limited Announces Board Changes	CI
Feb. 14	Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Syncom Formulations Limited announced that it has received INR 100.787496 million in funding

January 24, 2021

On January 25, 2021, Syncom Formulations (India) Limited (BSE:524470) closed the transaction.

Latest news about Syncom Formulations (India) Limited

Syncom Formulations Limited Announces Board Changes	Mar. 29	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Syncom Formulations Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 08	CI
Syncom Formulations Begins Commercial Production at Expanded Plant in Pithampur, India	23-08-21	MT
Syncom Formulations Limited Commences Commercial Production	23-08-21	CI
Syncom Formulations Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Syncom Formulations Limited Announces Commercial Production Starts from 30 June 2023	23-07-01	CI
Syncom Formulations Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-29	CI
Syncom Formulations Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-29	CI
Syncom Formulations Limited Announces Executive Changes	23-05-02	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Syncom Formulations Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Syncom Formulations Limited Approves the Declaration of Dividend for the Financial Year Ended 31 March 2022	22-09-20	CI
Syncom Formulations Sees Delay in Completion of Expansion Project	22-09-15	MT
Syncom Formulations Limited Announces Updates on its Project for Expansion Cum Modernisation of Existing Plant at Pithampur	22-09-15	CI
Syncom Formulations Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-13	CI
Syncom Formulations Limited Appoints Ruchi Jindal as an Additional Director	22-06-28	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
Syncom Formulations Limited Announces Executive Changes	21-11-13	CI
Syncom Formulations Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-13	CI
Syncom Formulations India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-06-30	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-02-12	CI
Syncom Formulations Limited announced that it has received INR 100.787496 million in funding	21-01-24	CI
Syncom Formulations Limited Announces Expansion of Existing Plant at Pithampur	20-12-18	CI
Syncom Formulations Limited announced that it expects to receive INR 100.787496 million in funding	20-12-17	CI

Chart Syncom Formulations (India) Limited

Duration

Period

Chart Syncom Formulations (India) Limited

More charts

Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. It is also engaged in the renting of properties. It manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Cefuroxime For Injection USP 750 mg and Gentamicin Injection BP 40 mg.

Sector

Pharmaceuticals

Calendar

2024-05-29 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SYNCOM FORMULATIONS (INDIA) LIMITED	-8.38%	158M
NOVO NORDISK A/S	+23.88%	562B
JOHNSON & JOHNSON	-6.10%	358B
MERCK & CO., INC.	+20.62%	322B
ABBVIE INC.	+8.49%	297B
ASTRAZENECA PLC	+13.40%	219B
NOVARTIS AG	+6.29%	199B
ROCHE HOLDING AG	-10.22%	196B
PFIZER, INC.	-9.55%	149B
AMGEN INC.	-5.70%	146B